Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Autor: Johnson JI; Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA., Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA

Publikováno v: British journal of cancer [Br J Cancer] 2001 May 18; Vol. 84 (10), pp. 1424-31.

Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.

Autor: Goldin A, Venditti JM, Macdonald JS, Muggia FM, Henney JE, Devita VT Jr

Publikováno v: European journal of cancer [Eur J Cancer (1965)] 1981 Feb; Vol. 17 (2), pp. 129-42.

Use of the KB cell line for in vitro cytotoxicity assays.

Autor: Shoemaker RH, Abbott BJ, Macdonald MM, Mayo JG, Venditti JM, Wolpert-DeFilippes MK

Publikováno v: Cancer treatment reports [Cancer Treat Rep] 1983 Jan; Vol. 67 (1), pp. 97.

Usefulness and limitations of murine tumor models for the identification of new antitumor agents.

Autor: Goldin A, Johnson RK, Venditti JM

Publikováno v: Antibiotics and chemotherapy [Antibiot Chemother (1971)] 1980; Vol. 28, pp. 1-7.

Circadian dependence of host and tumor responses to cyclophosphamide in mice.

Autor: Cardoso SS, Avery T, Venditti JM, Goldin A

Publikováno v: European journal of cancer [Eur J Cancer (1965)] 1978 Sep; Vol. 14 (9), pp. 949-54.